Physician profile
Dmitri V Vasin
NPI 1730132689
$215,047.75
in general payments reported to CMS, 2019-2025
14 companies · $7,784 in 2025
The $7,784 reported for 2025 was more than what 95% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74K · 2020: $37K · 2021: $40K · 2022: $44K · 2023: $13K · 2024: $13.94 · 2025: $7,784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,560 · Travel and Lodging: $4,090 · Food and Beverage: $1,477 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,825.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,560.00 |
| Travel and Lodging | $4,090.44 |
| Food and Beverage | $1,476.84 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $69,927.62 | 2020-2025 | Acthar |
| Mallinckrodt Enterprises LLC | $59,532.20 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $45,216.02 | 2021-2025 | |
| Vifor Pharma, INC. | $14,953.39 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $8,132.26 | 2023-2025 | |
| Travere Therapeutics, INC. | $6,303.32 | 2020-2023 | |
| Astrazeneca Pharmaceuticals LP | $5,839.23 | 2019-2023 | Lokelma |
| Calliditas Therapeutics US INC. | $3,610.78 | 2022-2023 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $1,175.00 | 2021 | |
| Novo Nordisk INC | $124.65 | 2025 | Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.51 | 2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $61.20 | 2019 | |
| Aurinia Pharma U.S., INC. | $27.51 | 2022 | |
| Akebia Therapeutics INC | $27.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitri Vasin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.